Case report: Bevacizumab-induced cerebrovascular events: a case series report and literature review
In clinical use, bevacizumab has improved the overall survival (OS) and progression-free survival (PFS) of malignant solid tumors, and the safe use of bevacizumab has gradually become the mainstream direction of clinical, nursing and pharmaceutical research. Bevacizumab is a humanized anti-VEGF drug...
Saved in:
| Main Authors: | Ke Chen, Boyang Jiang, Huiping Yan, Liu Yang, Zheling Chen |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-02-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1395129/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Use of Bevacizumab in the Treatment of Corneal Neovascularization
by: Tuba Çelik, et al.
Published: (2015-01-01) -
Atezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: 3‐year survival update and multi‐omics analysis
by: Jie Dai, et al.
Published: (2025-01-01) -
EFEKTIVITAS-BIAYA PENGGUNAAN BEVACIZUMAB DAN RANIBIZUMAB SEBAGAI ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR PADA PASIEN DENGAN GANGGUAN MATA: TINJAUAN SISTEMATIS
by: Nur Sidik Cahyono, et al.
Published: (2024-04-01) -
PERSPECTIVES ON USE OF BEVACIZUMAB IN PATIENTS WITH NEUROENDOCRINE TUMORS. CASE REPORT
by: G. S. Emelianova, et al.
Published: (2017-12-01) -
Severe late onset capillary leak syndrome post allo-HSCT successfully treated by bevacizumab: a case report
by: Song Xue, et al.
Published: (2025-01-01)